So we all know that prices are really high for many drugs in the United States. And you’ve been reporting on a case involving a big name American drug company. So Rebecca, you report on the pharmaceutical industry. Today, my colleague, Rebecca Robbins, on a case that suggests they can also create perverse incentives to hold new drugs back. sabrina taverniseįrom “The New York Times,” I’m Sabrina Tavernise, and this is “The Daily.”įor decades, drug companies have argued that patents are critical to bringing new drugs to market. Please review the episode audio before quoting from this transcript and email with any questions. While it has been reviewed by human transcribers, it may contain errors. This transcript was created using speech recognition software.
Transcript Why One Drug Company Held Back a Better Drug Drug companies say patents spur innovation.
0 kommentar(er)
